Patent US949331A successfully refreshed from Google Patents.
US3982012A
Expired / Lapsed
US
⏱️ 0.0 years remaining
4-Hydroxy-benzimidazole compounds and therapeutic compositions
Assignee: Roche Diagnostics GmbH
•
Filing: 1975-06-10
•
Granted: 1976-09-21
•
Expires: 1995-06-10
Abstract
Abstract New 4-hydroxy-benzimidazole compounds of the formula: OH ¦O-CH2-CH-CH2-NH-R1 (I) wherein R1 is straight-chained or branched alkyl and R2 is hydrogen atom or lower alkyl AND THE PHARMACOLOGICALLY COMPATIBLE SALTS THEREOF; ARE OUTSTANDINGLY EFFECTIVE IN THE TREATMENT AND PROPHYLAXIS OF CARDIAC AND CIRCULATORY DISEASES, AND PROVIDE SUBSTANTIALLY GREATER MARGINS OF SAFETY THAN PRIOR ART ADRENERGIC beta -RECEPTOR INHIBITORS.
Inventors
- 👤 Erich Fauland
- 👤 Wolfgang Kampe
- 👤 Max Thiel
- 👤 Wolfgang Bartsch
- 👤 Wolfgang Schaumann
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-01 04:57
CPC Classifications
C; C07; C07D; C07D235/00; C07D235/02; C07D235/04; C07D235/06; C07D235/08
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
41 words
4-Hydroxy-benzimidazole compound of the formula: ##EQU5## wherein R 1 is straight-chained or branched alkyl of up to 6 carbon atoms and R 2 is hydrogen atom or lower alkyl of up to 3 carbon atoms and the pharmacologically compatible salts thereof.
Claim 2
Dependent Claim
41 words
4-Hydroxy-benzimidazole compound of the formula: ##EQU5## wherein R 1 is straight-chained or branched alkyl of up to 6 carbon atoms and R 2 is hydrogen atom or lower alkyl of up to 3 carbon atoms and the pharmacologically compatible salts thereof.
Claim 3
Dependent Claim
13 words
4-Hydroxy-benzimidazole compound as claimed in claim 1 wherein R 1 is branched alkyl.
Claim 4
Dependent Claim
17 words
4-Hydroxy-benzimidazole compound as claimed in claim 1 wherein R 1 is alkyl up to 4 carbon atoms.
Claim 5
Dependent Claim
19 words
4-Hydroxy-benzimidazole compounds as claimed in claim 1 wherein R 1 is branched alkyl of 3 to 4 carbon atoms.
Claim 6
Dependent Claim
12 words
4-Hydroxy-benzimidazole compound as claimed in claim 1 wherein R 2 is hydrogen.
Claim 7
Dependent Claim
12 words
4-Hydroxy-benzimidazole compound as claimed in claim 1 wherein R 2 is methyl.
Claim 8
Dependent Claim
9 words
4-Hydroxy-benzimidazole compound as claimed in claim 1 designated 2-methyl-4-(3-tert.-butylamino-2-hydroxypropyloxy)-benzimidazole.
Claim 9
Dependent Claim
9 words
4-Hydroxy-benzimidazole compound as claimed in claim 1 designated 4-(3-tert.-butylamino-2-hydroxy-propyloxy)-benzimidazole.
Claim 10
Dependent Claim
9 words
4-Hydroxy-benzimidazole compound as claimed in claim 1 designated 2-methyl-4-(3-isopropylamino-2-hydroxypropyloxy)-benzimidazole.
Claim 11
Dependent Claim
9 words
4-Hydroxy-benzimidazole compound as claimed in claim 1 designated 4-(3-isopropylamino-2-hydroxy-propyloxy)-benzimidazole.
Claim 12
Dependent Claim
27 words
Therapeutic composition having adrenergic β-receptor inhibiting activity comprising a pharmaceutically acceptable carrier and an effective amount of at least one 4-hydroxy-benzimidzole compound as claimed in claim 1.
Claim 13
Dependent Claim
66 words
Method for the treatment or prophylaxis of cardiac and circulatory diseases which method comprises administering to the afflicted subject a therapeutically effective amount of a 4-hydroxy-benzimidazole compound of the formula ##EQU6## wherein R 1 is straight-chained or branched alkyl of up to 6 carbon atoms and R 2 is hydrogen atom or lower alkyl of up to 3 carbon atoms and the pharmacologically compatible salts thereof.
Claim 14
Dependent Claim
66 words
Method for the treatment or prophylaxis of cardiac and circulatory diseases which method comprises administering to the afflicted subject a therapeutically effective amount of a 4-hydroxy-benzimidazole compound of the formula ##EQU6## wherein R 1 is straight-chained or branched alkyl of up to 6 carbon atoms and R 2 is hydrogen atom or lower alkyl of up to 3 carbon atoms and the pharmacologically compatible salts thereof.
Claim 15
Dependent Claim
31 words
Method as claimed in claim 12 wherein the compound is applied at a dosage of about 4 to 160 mg. per day per 75 kg. of body weight of said subject.
Claim 16
Dependent Claim
21 words
Method as claimed in claim 12 wherein said compound is selected from the group consisting of 2-methyl-4-(3-tert.-butylamino-2-hydroxy-propyloxy)-benzimidazole, 4-(3-tert.-butylamino-2hydroxy-propyloxy)-benzimidazole, 2-methyl-4-(3-isopropylamino-2-hydroxy-propyloxy)-benzimidazole, and 4-(3-isopropylamino-2hydroxy-propyloxy)-benzimidazole.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1979-09-21 | 1980-03-22 | 1980-09-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1983-09-21 | 1984-03-22 | 1984-09-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1987-09-21 | 1988-03-22 | 1988-09-21 | $7700.00 | Window Closed / Lapsed |